Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wipin
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
01:48pm, Wednesday, 15'th Jan 2025
NEW YORK , Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceut
The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – REGN
12:48pm, Wednesday, 15'th Jan 2025
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders
10:44am, Wednesday, 15'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
10:34am, Wednesday, 15'th Jan 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you
Regeneron Pharmaceuticals Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
10:15am, Wednesday, 15'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc
Regeneron: Phase III Success In Skin Cancer For Libtayo
08:30am, Wednesday, 15'th Jan 2025
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition, contribu
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline
07:30am, Wednesday, 15'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regenero
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc.
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – REGN
04:30pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
REGN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / January 14, 2025 / Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faces a securities fraud class action after
SAN DIEGO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 20
